JAK inhibition during the early phase of SARS-CoV-2 infection worsens kidney injury by suppressing endogenous antiviral activity in mice

DOI Web Site 参考文献42件
  • Hibiki Sakai
    Laboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan
  • Hiroyasu Kamuro
    Laboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan
  • Nagisa Tokunoh
    Vaccine Creation Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
  • Takeshi Izawa
    Laboratory of Veterinary Pathology, Osaka Metropolitan University Graduate School of Veterinary Science, Osaka, Japan
  • Shigeyuki Tamiya
    Vaccine Creation Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
  • Ayaha Yamamoto
    Laboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan
  • Shota Tanaka
    Laboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan
  • Daisuke Okuzaki
    Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
  • Chikako Ono
    Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
  • Yoshiharu Matsuura
    Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
  • Yoshiaki Okada
    Laboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan
  • Yasuo Yoshioka
    Vaccine Creation Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
  • Yasushi Fujio
    Laboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan
  • Masanori Obana
    Laboratory of Clinical Science and Biomedicine, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan

書誌事項

公開日
2024-06-01
資源種別
journal article
DOI
  • 10.1152/ajprenal.00011.2024
公開者
American Physiological Society

この論文をさがす

説明

<jats:p> Patients frequently present with acute kidney injury or abnormal urinary findings after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we investigated how the kidneys respond during SARS-CoV-2 infection using a murine coronavirus disease 2019 (COVID-19) model and showed that Janus kinase-mediated endogenous antiviral activity protects against kidney injury in the early phase of SARS-CoV-2 infection. These findings provide valuable insights into the renal pathophysiology of COVID-19. </jats:p>

収録刊行物

参考文献 (42)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ